update in cardiology: 2012 james a. coman md, facc president and founder, heart rhythm institute of...
TRANSCRIPT
Update in Cardiology: 2012
James A. Coman MD, FACC
President and Founder,Heart Rhythm Institute of Oklahoma
Tulsa, Oklahoma
Disclosures
Ischemic Heart Disease
• Ranolazine (Ranexa) – indicated for reduction of anginaDose 500 mg BID and increase to 1000 mg BIDAvoid concomitant CYP3 inhibitors
• Fish Oil nonhelpful
Ischemic Heart Disease
• Post Cardiac Arrest CoolingLowers mortality and improves neurologic outcomes32º C for 24 hoursWatch for infection and coagulopathyCan’t be used in patients with head trauma, CVA, or preexisting coagulopathy
Acute MI
• Drug Eluting Stentsaccount for 75% of all stentslower restenosis ratesrequire one year of ASA, andplavix, prasugrel, or ticagrelor
• IABP placement found non helpful in AMI shock
Valvular Heart Disease
Prevalence of valve disease in the population
The Next Cardiac Epidemic
Nikomo et al, Lancet 2006; 368: 1005
Pre
vela
nce
of m
ode
rate
or
seve
re v
alv
e d
ise
ase
(%
)
Severe Aortic Stenosis Without Surgery:
Worse Than Most Metastatic Cancers
5-Year Survival
Su
rviv
al,
%
* National Institutes of Health. National Cancer Institute. Surveillance Epidemiology and End Results. Cancer Stat Fact Sheets.http://seer.cancer.gov/statfacts/. Accessed November 16, 2010.† Using constant hazard ratio. Data on file, Edwards Lifesciences LLC.
†
Transcatheter Aortic Valve Implantation (TAVI)
Smith CR et al. N Engl J Med 2011;364:2187-2198.
All Cause Mortality (ITT)Landmark Analysis
All
Ca
use
Mo
rta
lity
(%)
Months
Mortality 0-1 yr Mortality 1-2yr
Standard Rx TAVR
HR [95% CI] =0.57 [0.44, 0.75]
p (log rank) < 0.0001
HR [95% CI] =0.58 [0.37, 0.92]
p (log rank) = 0.019450.7%
30.7%
35.1%
18.2%
Numbers at Risk
TAVR 179 138 124 110 83 Standard Rx 179 121 85 62 42
44.2
10.2 10.9 10.610.6
0.64
1.55 1.61 1.58 1.68
0.0
0.5
1.0
1.5
2.0
2.5
0
10
20
30
40
50
60
70
Baseline 30 Day 1 Year 2 Year 3 Year
Me
an
Gra
die
nt (
mm
Hg
)
Error bars = ± 1 Std Dev
EOA
Mean Gradient
N = 158
N = 162
N = 137
N = 143
N = 84
N = 89
N = 65
N = 65
N = 9
N = 9
AV
A (cm
²)Mean Gradient &
Valve Area
Transcatheter valves provide excellent hemodynamics and appear very durable to 3 years
Months
348 289 252 143 65
351 247 232 138 63
No. at Risk
TAVR
AVR
28.0
26.5
HR [95% CI] =0.95 [0.73, 1.23]
P (log rank) = 0.70
PARTNER COHORT A (high risk)All-Cause Mortality or Stroke (ITT)
All Patients (N=699)
Complications• Device embolization
• Aortic insufficiency
• Coronary occlusion
• Root rupture
• Stroke
• AV block – pacemaker
• Vascular complications – bleeding
• Acute Renal Failure
Device Embolization
Para-valvular Regurgitation
Iliac Avulsion
Embolic Materialafter TAVR
Embolic Material
Embolic Material
Day 6 Post-implant
Who Might Be a Candidate for TAVR?
• Severe aortic stenosis – AVA < 0.8
• Symptomatic
• Chest pain, CHF, syncope
• Inoperable
• Opinion of two surgeons
• Porcelain aorta
• Multiple sternotomies
• Chest radiation
• COPD
• General frailty
What the Patient Should Know
• Survival (inoperable cohort) – 70% one year and 60% two year survival. Late deaths mostly noncardiac
• Stroke – 5%
• Pacemaker – 3.5%
Radiofrequency Ablation
• Targeted RhythmsAVNRTAccessory Pathway RhythmsAtrial FlutterEctopic Atrial RhythmsPost Congenital Repair RhythmsNormal Heart VT
AF
Radiofrequency Ablation
• Success rates of 95-100% for all but atrial fibrillation
• Complication rates approaching zero
• Home after 4 hours
Atrial Fibrillation
• Mechanism: starts from high frequency impulses from the pulmonary veins and continues from vortices of re-entry within the atria
• Treatment with membrane active drugs carries risk, making treatment appropriate only for the young OR symptomatic patients
Atrial Fibrillation RFA• Success rate from 40 to 80%
• Complication rate: 1% chance of CVA1% chance of pulmonary vein stenosis
• Long procedure time
• High doses of radiation for patient and physician
• Ideal patient has highly symptomatic AF, failed multiple drugs, and has PAF with a normal heart
Cryoballoon
Atrial Fibrillation• CVA risk can ONLY be addressed by warfarin long
term (INR 2-3), dabigatran, or rivaroxaban
• Risk factors necessitating anticoagulation include:HTN, DM, CHF,h/o thrombus formation elsewhere,age > 65-75, vascular disease, or female
gender
• CHADS2-Vasc Score: CHF, HTN, Age>65 (1) >75 (2), DM, CVA or Thromboembolism (2), Vascular Disease, and female gender Scores of 0 and 1 need ASA, others anticoagulation
Atrial Fibrillation• Drug treatment
• Dofetilide
• Amiodarone
• Sotalol
• Flecainide
• Dronedarone
CHF
Courtesy of Dr. Auricchio, University of Magdeburg, Germany.
The Implanted LV Lead
LAO View Lateral Coronary Vein Placement
Patient Selection• Any Class of CHF on appropriate
medical therapy with IVCD (QRS > 120ms) and LVEF <35%
• Patients post AV nodal ablation
• “Candidates for living”
• Be cautious of choosing only the “healthy”
Sudden Cardiac Death
• 350,000 to 550,000 people die each year in the US from SCD
• 97% of people die from their first episode of SCD
ANNUAL DEATHS IN U.S.
0
50,000
100,000
150,000
200,000
250,000
300,000
SCD CVA Lung CA BreastCA
AutoAcc.
AIDS Fires1NASPE, May 20002American Heart Association 20003National Cancer Institute 20014National Transportation Safety Board, 20005Center for Disease Control 20016NFPA, US Facts & Figures, 2000
CAST-I and other AAD Trials
80
85
90
95
100
0 91 182 273 364 455
Days After Randomization
Pat
ien
ts W
ith
ou
t E
ven
t (%
)
Placebo (n = 743)
Encainide or Flecainide
SWORD – D sotolol
CASH -propafenone
EMIAT - amiodarone
Primary Prevention ICD Trials1.0
0.8
0.6
0.4
0.2
0.0
0 1 2 3 4 5Year
Pro
ba
bili
ty o
f s
urv
iva
l
MADIT I - Conv Tx
MADIT I - ICD
MADIT II - ICD MUSTT - ICD
Sudden Cardiac Death
• One patient dies each minute in the US from SCD
• 1440 patients died yesterday
• Statistically, 600 saw a health care provider in the past year
Cost Analysis
050
100150200250300350400
1,00
0
Cost/YOLS
Conclusions• Cooling post cardiac arrest is
beneficial
• Angina can be treated even when revascularization can no longer be performed
• AS can be treated easily percutaneously for inoperable patients
Conclusions• Most abnormal rhythms can be ablated
• Atrial fibrillation is potentially ablatable
• Many patients with AF need anticoagulation. Risk assessment with CHADS2-Vasc should be done
• Cardiac Resynchronization Therapy (BiV pacing) is the treatment of choice for CHF after appropriate medications in patients with a wide QRS
Conclusions
• ICD’s are the best protection against SCD – America’s number one killer
• Patients with LVEF < 35% likely need an ICD
• Patients with LVEF <35% and QRS >120ms need CRT-D